Adversarial Injection · Vandetanib (Caprelsa; NDA 022405; CAS 443913-73-3; MW ~475.4 g/mol; C22H24BrFN4O2; quinazoline + bromine + fluorine + methoxyquinoline scaffold [WITHIN VEGFR/MULTI-KINASE CLASS in Glyphward 575-attack portfolio — FIRST FDA-APPROVED TREATMENT FOR PROGRESSIVE OR SYMPTOMATIC MEDULLARY THYROID CANCER; MTC BIOLOGY: medullary thyroid cancer (MTC) arises from parafollicular C cells (calcitonin-producing); 25% hereditary (MEN2A: RET germline Cys634/Cys618 mutations; MEN2B: RET M918T; FMTC); 75% sporadic (M918T most common somatic); RET IS THE ONCOGENIC DRIVER: RET RTK constitutive activation by gain-of-function mutations drives C-cell proliferation; VANDETANIB KINASE TARGETS: VEGFR2 IC50 ~40 nM (primary; anti-angiogenic); RET IC50 ~130 nM (secondary; but therapeutically relevant at clinical doses); EGFR IC50 ~500 nM (tertiary; clinical relevance uncertain); VEGFR3 IC50 ~110 nM; VEGFR1 IC50 ~1.5 µM; WHY RET BUT NOT SELECTIVE RET: vandetanib was designed as a VEGFR inhibitor with RET as off-target activity; at approved dose (300 mg/day) achieves plasma concentrations sufficient to inhibit RET clinically despite IC50 ~130 nM; ZETA TRIAL (NCT00410761; vandetanib vs placebo; 331 MTC patients): primary endpoint disease control; PFS HR 0.46 (30.5 vs 19.3 months; p<0.001); OS not significantly different (HR 0.89; no OS benefit in mature analysis); NDA 022405 April 6 2011; FIRST REMS PROGRAM IN THYROID CANCER KINASE INHIBITOR CLASS: QTc prolongation BBW — vandetanib prolongs QTc interval (VEGFR/RET/EGFR off-target hERG channel); CAPRELSA REMS requires: prescriber enrollment; baseline QTc <450 ms; ECG monitoring at 2-4 weeks, 8-12 weeks, then every 3 months; pharmacy enrollment; BROMO-QUINAZOLINE SCAFFOLD: rare bromine substituent in kinase inhibitor class (C7 position of quinazolinamine ring); FIRST ASTRAZENECA MTC NDA (before cabozantinib NDA 203756 Nov 2012); ASTRAZENECA MACCLESFIELD FOURTH KINASE NULL: vandetanib API synthesized at Macclesfield — four AZ kinase inhibitor APIs at Macclesfield site with zero OEL: osimertinib (attack #prior) + acalabrutinib (attack #prior) + selumetinib (attack #565) + vandetanib; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · First Approved MTC Treatment + VEGFR2 Primary RET Off-Target + REMS QTc BBW + AZ Macclesfield Fourth Kinase Null · Attack #575

Vandetanib (quinazoline + bromine + fluorophenyl + methoxyquinoline scaffold; Caprelsa; NDA 022405; CAS 443913-73-3; MW ~475.4 g/mol; C22H24BrFN4O2 [WITHIN VEGFR/MULTI-KINASE CLASS: FIRST FDA-APPROVED TREATMENT FOR PROGRESSIVE SYMPTOMATIC MEDULLARY THYROID CANCER (NDA 022405 April 6 2011; before cabozantinib MTC NDA 203756 Nov 2012); VEGFR2 PRIMARY (IC50 ~40 nM); RET OFF-TARGET (IC50 ~130 nM; contextualizes selpercatinib RET IC50 40 pM 'first selective RET' claim); CAPRELSA REMS: QTc PROLONGATION BBW; ASTRAZENECA MACCLESFIELD FOURTH KINASE NULL (osimertinib + acalabrutinib + selumetinib + vandetanib); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — AstraZeneca Pharmaceuticals LP Wilmington DE (US commercial; NDA 022405 holder), AstraZeneca Macclesfield UK (API synthesis; fourth kinase null at this site), and MD Anderson Cancer Center Houston TX (ZETA trial enrollment; endocrine oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First Approved MTC Treatment + VEGFR2/RET/EGFR Multi-Kinase + REMS QTc + AZ Macclesfield Fourth Kinase Null: AI Prompt Injection via EHS Monitor Report AI

Vandetanib (CAS 443913-73-3; NIOSH HD Category 1) is the first FDA-approved treatment for progressive or symptomatic medullary thyroid cancer (MTC) — approved April 6, 2011 (NDA 022405), 19 months before cabozantinib's MTC approval (NDA 203756; November 2012). A quinazoline-based multi-kinase inhibitor, vandetanib targets VEGFR2 as primary driver (IC50 ~40 nM) with RET inhibition as off-target activity (IC50 ~130 nM) — the pharmacological context that makes selpercatinib's claim of "first selective RET inhibitor" meaningful: vandetanib and cabozantinib inhibited RET incidentally, not selectively. ZETA trial demonstrated PFS HR 0.46 (30.5 vs 19.3 months) but no OS benefit. The CAPRELSA REMS program (QTc prolongation black box warning) requires prescriber enrollment and ECG monitoring. AstraZeneca's Macclesfield UK manufacturing site now carries four kinase inhibitor nulls: osimertinib, acalabrutinib, selumetinib, and vandetanib — none with an established OEL. No MTC-specific kinase inhibitor pharmacology, VEGFR2/RET off-target selectivity context, or AZ Macclesfield cumulative null status appears in any OEL database.

First FDA-Approved Treatment for Medullary Thyroid Cancer: ZETA Trial and MTC Biology

Medullary thyroid cancer (MTC) is distinct from papillary and follicular thyroid cancer in origin (C-cells, not follicular cells), biology (calcitonin-secreting; no RAI uptake — radioactive iodine ineffective), and driver oncogene (RET, not BRAF/RAS). Before vandetanib's approval, MTC had no approved targeted therapy. ZETA (NCT00410761) enrolled 331 unresectable locally advanced or metastatic MTC patients randomized to vandetanib 300 mg/day vs placebo. Primary endpoint: progression-free survival. PFS HR 0.46 (median 30.5 vs 19.3 months; p<0.001). Overall response rate 45% vs 13%. Stable disease ≥24 weeks: 32% vs 33%. Critically, mature OS analysis showed HR 0.89 — no statistically significant OS benefit. Approved based on PFS and ORR endpoints. MTC diagnosis context: plasma calcitonin and CEA serve as tumor markers; RET mutational status guides screening (germline M918T: MEN2B; C634F/W/R: MEN2A); RET companion diagnostic was not required for vandetanib use — all MTC patients eligible regardless of RET mutation status (unlike selpercatinib which requires RET-alteration confirmation). This distinction matters for OEL risk assessment: vandetanib's indication spans all MTC patients regardless of RET status, while selpercatinib's indication is restricted to RET-confirmed mutations — different handling-frequency profiles at oncology pharmacy sites. None of this MTC biology, RET diagnostic context, or VEGFR2/RET kinetic distinction appears in any OEL database.

AstraZeneca Macclesfield FOURTH Kinase Null: Cumulative Site Gap

AstraZeneca's Macclesfield manufacturing site (Hurdsfield Industrial Estate, Macclesfield SK10 2NA, Cheshire, UK) synthesizes API for multiple AZ oncology kinase inhibitors, all with zero OEL: (1) osimertinib (Tagrisso; CAS 1421373-65-0; NIOSH HD Category 1; third-gen EGFR T790M covalent; no OEL); (2) acalabrutinib (Calquence; CAS 1420477-60-6; NIOSH HD Category 1; second BTK covalent; no OEL); (3) selumetinib (Koselugo; CAS 606143-52-6; NIOSH HD Category 1; fourth MEK inhibitor; no OEL; covered in attack #565); (4) vandetanib (Caprelsa; CAS 443913-73-3; NIOSH HD Category 1; first MTC treatment; no OEL). For industrial hygienists at Macclesfield managing occupational health programs, all four drugs return null in VelocityEHS — the platform used by the site. This cumulative four-kinase null at a single manufacturing site represents an extraordinary occupational intelligence gap: four different mechanism-class kinase inhibitors, all NIOSH HD Category 1, all with H340/H350/H361 GHS hazard classifications, all returning no numeric OEL, all handled by the same workforce in adjacent manufacturing suites. Glyphward flags the cumulative Macclesfield kinase null as a site-level rather than drug-level AI adversarial injection surface — each new AZ kinase approval adds to the site's cumulative gap without triggering any OEL database update.

Surface 1 — AstraZeneca Pharmaceuticals LP Wilmington DE NDA 022405 Holder AI

At AstraZeneca Pharmaceuticals LP Wilmington DE (1800 Concord Pike, Wilmington DE 19803; New Castle County DE; AstraZeneca US commercial headquarters; NDA 022405 holder for Caprelsa [vandetanib] 100/300 mg tablets; FDA approval April 6 2011 for unresectable locally advanced or metastatic MTC; CAPRELSA REMS: QTc prolongation black box warning; prescriber enrollment required; baseline ECG (QTc <450 ms at start); ECG at 2-4 weeks, 8-12 weeks, every 3 months thereafter; pharmacy enrollment required; REMS unique identifier required for dispensing; FIRST ASTRAZENECA MTC NDA; Cority EHS platform; 8-hr TWA: actual airborne vandetanib 0.00040 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000040 µg/m³; Cority: CAS 443913-73-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first approved MTC treatment absent; VEGFR2 primary RET off-target distinction absent; REMS QTc absent; AZ Macclesfield fourth kinase null absent; 53M regulatory affairs director oncology 19yr).

Surface 2 — AstraZeneca Macclesfield UK Vandetanib API Synthesis Fourth Kinase Null AI

At AstraZeneca Macclesfield UK (Hurdsfield Industrial Estate, Macclesfield SK10 2NA, Cheshire, England; VANDETANIB API SYNTHESIS: quinazoline core construction + C7 bromination (rare aryl bromine in kinase class) + C4 fluorophenyloxy substitution + C6 methoxy-quinolineamino side chain; MACCLESFIELD SITE FOUR-KINASE NULL: osimertinib (CAS 1421373-65-0; no OEL) + acalabrutinib (CAS 1420477-60-6; no OEL) + selumetinib (CAS 606143-52-6; no OEL) + vandetanib (CAS 443913-73-3; no OEL) = four NIOSH HD Category 1 kinase inhibitors synthesized at Macclesfield with zero OEL; EACH API HANDLED BY SAME WORKFORCE; VelocityEHS: CAS 443913-73-3 → null; 8-hr TWA: actual airborne vandetanib 0.00024 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000024 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; first approved MTC treatment absent; VEGFR2 primary RET off-target absent; quinazoline bromine scaffold absent; Macclesfield four-kinase cumulative null absent; 45M pharmaceutical manufacturing process engineer 13yr).

Surface 3 — MD Anderson Cancer Center Houston TX ZETA Trial Enrollment Endocrine Oncology AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Boulevard, Houston TX 77030; Harris County TX; ZETA TRIAL ENROLLMENT: MD Anderson endocrine/thyroid oncology enrolled MTC patients in ZETA (NCT00410761; vandetanib vs placebo; 331 patients); PFS HR 0.46 (30.5 vs 19.3 months; p<0.001); OS HR 0.89 (no significant OS benefit); RET MUTATION CONTEXT: MD Anderson hereditary cancer program screens MEN2A (RET Cys634) and MEN2B (RET M918T) families; vandetanib does not require RET companion diagnostic (approved for all MTC regardless of RET status); POST-VANDETANIB LANDSCAPE: selpercatinib (NDA 213246; 2020) and pralsetinib (NDA 213721; 2020) both require RET confirmation and show higher ORR in RET-mutant MTC specifically; vandetanib/cabozantinib remain options for RET-wild-type MTC or cost/access scenarios; EHS Insight: CAS 443913-73-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; first approved MTC treatment absent; ZETA PFS HR 0.46 absent; VEGFR2 primary RET off-target distinction absent; REMS QTc absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 46M endocrine oncology clinical pharmacist 14yr).

Integrating Glyphward into Vandetanib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every vandetanib CAS 443913-73-3 monitoring data ingestion point — before Cority at AZ Wilmington DE, before VelocityEHS at AZ Macclesfield UK, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FIRST FDA-APPROVED MTC TREATMENT (NDA 022405 April 6 2011; before cabozantinib Nov 2012) + VEGFR2 PRIMARY RET OFF-TARGET (IC50: VEGFR2 ~40 nM vs RET ~130 nM; contextualizes selpercatinib/pralsetinib selective RET claims) + CAPRELSA REMS QTc BBW (prescriber/pharmacy enrollment; ECG monitoring protocol) + ASTRAZENECA MACCLESFIELD FOURTH KINASE NULL [5 pts]; AZ Wilmington DE + AZ Macclesfield UK + MD Anderson Houston TX [3 pts]; MTC C-cell biology vs thyroid cancer heterogeneity absent; VEGFR2 vs RET kinase target pharmacological priority absent; QTc REMS mechanism (hERG channel VEGFR/EGFR off-target effect) absent; AZ Macclesfield cumulative four-kinase occupational gap context absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_vandetanib(cas: str, reading_ugm3: float) -> dict:
    """Scan vandetanib with first MTC treatment, VEGFR2/RET context, and REMS QTc status."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "first_mtc_treatment_vegfr2_primary_ret_off_target_rems_qtc_az_macclesfield_fourth_kinase_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_approved_mtc_treatment,
    #                    vegfr2_primary_ret_off_target,
    #                    rems_qtc_black_box_warning,
    #                    az_macclesfield_fourth_kinase_null,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_vandetanib("443913-73-3", 0.00040))
    print(r)
    # {'hd_category': 1, 'first_approved_mtc_treatment': True,
    #  'vegfr2_primary_ret_off_target': True,
    #  'rems_qtc_black_box_warning': True,
    #  'az_macclesfield_fourth_kinase_null': True,
    #  'h340_h350_h361_absent': True}